Does Rallies show Form 4 insider transactions for PGEN?

Yes. Rallies tracks PGEN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is PGEN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PGEN. It does not provide personalized investment advice.

PGEN (Precigen, Inc. Common Stock) Stock Analysis - Insider Trades

Precigen, Inc. Common Stock (PGEN) is a publicly traded Healthcare sector company. As of May 21, 2026, PGEN trades at $4.28 with a market cap of $1.45B and a P/E ratio of -3.12. PGEN moved +2.40% today. Year to date, PGEN is +2.15%; over the trailing twelve months it is +202.84%. Its 52-week range spans $0.65 to $5.47. Analyst consensus is buy with an average price target of $11.00. Rallies surfaces PGEN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading PGEN stock inside the company?

Recent PGEN insider activity includes KIRK RANDAL J sold 1.11M, KIRK RANDAL J sold 50.80K, KIRK RANDAL J sold 370.85K, KIRK RANDAL J sold 152.06K, and KIRK RANDAL J sold 50.80K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

PGEN Key Metrics

Key financial metrics for PGEN
Metric	Value
Price	$4.28
Market Cap	$1.45B
P/E Ratio	-3.12
EPS	$-1.37
Dividend Yield	0.00%
52-Week High	$5.47
52-Week Low	$0.65
Volume	273
Avg Volume	0
Revenue (TTM)	$9.68M
Net Income	$-250.64M
Gross Margin	0.00%

Recent PGEN Insider Trades

KIRK RANDAL J sold 1.11M (~$3.66M) on Mar 30, 2026.
KIRK RANDAL J sold 50.80K (~$167.63K) on Mar 30, 2026.
KIRK RANDAL J sold 370.85K (~$1.22M) on Mar 30, 2026.
KIRK RANDAL J sold 152.06K (~$501.81K) on Mar 30, 2026.
KIRK RANDAL J sold 50.80K (~$167.63K) on Mar 30, 2026.

Latest PGEN News

Precigen Reports $21.6M Q1 PAPZIMEOS Revenue and $0.02 EPS Loss — May 13, 2026
Precigen Expects Q1 Revenue Above $18M After $3.4M Q4 PAPZIMEOS Sales — Apr 7, 2026
Precigen to Launch Papziemos After Early Approval, Shares Up 89.8% — Mar 5, 2026

PGEN Analyst Consensus

2 analysts cover PGEN: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $11.00.

Common questions about PGEN

Who is trading PGEN stock inside the company?: Recent PGEN insider activity includes KIRK RANDAL J sold 1.11M, KIRK RANDAL J sold 50.80K, KIRK RANDAL J sold 370.85K, KIRK RANDAL J sold 152.06K, and KIRK RANDAL J sold 50.80K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PGEN?: Yes. Rallies tracks PGEN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PGEN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PGEN. It does not provide personalized investment advice.